Prediction of Drug Distribution in Rat and Humans Using an Artificial Neural Networks Ensemble and a PBPK Model

[1]  Paulo Paixão,et al.  Tissue-to-blood distribution coefficients in the rat: utility for estimation of the volume of distribution in man. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Paulo Paixão,et al.  Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model. , 2012, International journal of pharmaceutics.

[3]  A. Vulpetti,et al.  The experimental uncertainty of heterogeneous public K(i) data. , 2012, Journal of medicinal chemistry.

[4]  Malcolm Rowland,et al.  PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. , 2011, Journal of pharmaceutical sciences.

[5]  Malcolm Rowland,et al.  PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.

[6]  Xiaohui Fan,et al.  Why QSAR fails: an empirical evaluation using conventional computational approach. , 2011, Molecular pharmaceutics.

[7]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[8]  Haiyan Li,et al.  Contribution of molecular properties to extrapolation of the volume of distribution in human from preclinical animal species data , 2010, Biopharmaceutics & drug disposition.

[9]  Paulo Paixão,et al.  Prediction of the in vitro permeability determined in Caco-2 cells by using artificial neural networks. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  Roberto Todeschini,et al.  Molecular descriptors for chemoinformatics , 2009 .

[11]  Leslie Z. Benet,et al.  Effects of Drug Transporters on Volume of Distribution , 2009, The AAPS Journal.

[12]  Paulo Paixão,et al.  Prediction of drug distribution within blood. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.

[14]  Arthur M. Doweyko,et al.  QSAR: dead or alive? , 2008, J. Comput. Aided Mol. Des..

[15]  M. Abraham,et al.  A data base for partition of volatile organic compounds and drugs from blood/plasma/serum to brain, and an LFER analysis of the data. , 2006, Journal of pharmaceutical sciences.

[16]  H. Mewes,et al.  Can we estimate the accuracy of ADME-Tox predictions? , 2006, Drug discovery today.

[17]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[18]  M. Abraham,et al.  Air to muscle and blood/plasma to muscle distribution of volatile organic compounds and drugs: linear free energy analyses. , 2006, Chemical research in toxicology.

[19]  Brian J. Taylor,et al.  Methods and Procedures for the Verification and Validation of Artificial Neural Networks , 2005 .

[20]  Igor V. Tetko,et al.  Virtual Computational Chemistry Laboratory – Design and Description , 2005, J. Comput. Aided Mol. Des..

[21]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[22]  M. Abraham,et al.  Air to blood distribution of volatile organic compounds: a linear free energy analysis. , 2005, Chemical research in toxicology.

[23]  I. Tetko,et al.  Application of ALOGPS to predict 1-octanol/water distribution coefficients, logP, and logD, of AstraZeneca in-house database. , 2004, Journal of pharmaceutical sciences.

[24]  L. Berezhkovskiy,et al.  Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. , 2004, Journal of pharmaceutical sciences.

[25]  J. V. Turner,et al.  Pharmacokinetic parameter prediction from drug structure using artificial neural networks. , 2004, International journal of pharmaceutics.

[26]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery. 3. Modeling Blood-Brain Barrier Partitioning Using Simple Molecular Descriptors , 2003, J. Chem. Inf. Comput. Sci..

[27]  Yi Li,et al.  In silico ADME/Tox: why models fail , 2003, J. Comput. Aided Mol. Des..

[28]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[29]  Igor V. Tetko,et al.  Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices , 2001, J. Chem. Inf. Comput. Sci..

[30]  F. Theil,et al.  Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. , 2001, Journal of pharmaceutical sciences.

[31]  S. Hadjitodorov,et al.  Empirical versus mechanistic modelling: Comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates , 1999, AAPS PharmSci.

[32]  Malik Magdon-Ismail,et al.  No Free Lunch for Early Stopping , 1999, Neural Computation.

[33]  Lutz Prechelt,et al.  Automatic early stopping using cross validation: quantifying the criteria , 1998, Neural Networks.

[34]  G. Juliusson,et al.  Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  Klaus-Robert Müller,et al.  Asymptotic statistical theory of overtraining and cross-validation , 1997, IEEE Trans. Neural Networks.

[36]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[37]  S. So,et al.  Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors. , 1992, Journal of medicinal chemistry.

[38]  Yuichi Sugiyama,et al.  In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[39]  I Alphabetical Listing Volume Ii , 2021 .

[40]  Paola Gramatica,et al.  On the development and validation of QSAR models. , 2013, Methods in molecular biology.

[41]  Stephen R. Johnson,et al.  The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy) , 2008, J. Chem. Inf. Model..

[42]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[43]  F. Theil,et al.  A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.

[44]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.